May is Women's Health Month: What the Market Offers for Hormonal Balance and Longevity
In the US, May is declared Women's Health Month; the focus is on hormonal foundations, active longevity, and new clinical data on the benefits of ginger for PCOS and marine collagen.
The fact that May is officially Women's Health Month in the US, with federal agencies promoting the slogan "Prevention, Innovation, and Impact," is just the tip of the iceberg. For the industry, this calendar marker means much more than an awareness campaign. It's a moment when peak marketing budgets, a wave of new clinical publications, and a reset of consumer interest in hormonal health and active longevity converge. We see this May not as a series of articles about the benefits of ginger for PCOS or collagen for skin, but as a strategic turning point: the women's health market is moving from niche "female" products to the mainstream longevity economy.
[The Core]: What's Really Happening
Formally, the month's agenda is screenings, prevention, and awareness. But the real story is different: the merging of the two most profitable verticals in the wellness market—hormonal therapy and evidence-based anti-aging. Previously, "women's health" was a ghetto of pink packaging, prenatal vitamins, and sanitary pads. Now, in May 2026, this category is absorbing the entire active longevity segment, because the female body has become the primary model for studying aging. Menopause is not a separate problem but an ideal cellular model for studying collagen loss, bone density, and cognitive decline. Therefore, every major player, from Nestlé Health Science to L'Oréal, is repackaging their anti-aging lines with hormone-oriented storytelling.
The second shift we see is a sharp narrowing of the gap between "natural" and "pharmaceutical" in the women's segment. The study of ginger for PCOS is not just an academic curiosity. It shows that functional foods and spices are beginning to follow the same path of evidence as prescription drugs. This opens the door for a new product category—"hormonally active nutraceuticals"—positioned not as supplements but as functional food with clinically proven effects on the endocrine system.
Timeline and Context
To understand how the market reached this point, just look at three events from recent days.
On May 10, 2026, National Women's Health Week in the US started under federal patronage, and North Dakota HHS issued recommendations focusing on chronic diseases and "evidence-based care." This set the information backdrop and legitimized the topic for mass media. Simultaneously, on May 4, a randomized double-blind placebo-controlled study on the effect of ginger on the hormonal profile of women with PCOS was published in ScienceDirect. The results—reduced total testosterone and free androgen index, increased SHBG, and decreased amenorrhea frequency—were released precisely to coincide with Women's Health Month. This is no coincidence; it's a coordinated launch of scientific evidence for future product lines.
Meanwhile, in March 2026, an updated meta-analysis on collagen confirmed improved skin elasticity and hydration but explicitly stated that collagen does not eliminate wrinkles. This is a key detail: the industry can no longer lie about "anti-aging elixirs," so it's shifting to a more honest and science-driven niche—"hormonal aging" and menopausal care. That same March, researchers from Anglia Ruskin University emphasized that collagen works best for postmenopausal women who have lost up to 30% of skin collagen. Thus, "general anti-aging" becomes "hormone-specific anti-aging," a much stronger unique selling proposition.
Third: the Femtech market, according to recent estimates, reached $55.88 billion in 2026 and is expected to nearly double to $118.99 billion by 2030. The women's digital health segment is valued at $5.28 billion. This means venture capital funds are actively seeking startups at the intersection of hormone tracking, predictive menopause analytics, and AI diagnostics for endocrine disorders. May 2026 is not just an awareness month but a showcase for investors.
Who Wins and Who Loses
Winners:
- Functional foods with hormonal specificity. The ginger study is just the tip. Expect explosive sales growth of spices and extracts positioned for "metabolic and hormonal balance." Manufacturers like Gaia Herbs and Traditional Medicinals are already preparing "PCOS Support" lines with ginger, cinnamon, and myo-inositol. The price per package of such functional tea can reach €35, with margins higher than standard supplements.
- Femtech platforms with AI diagnostics. Flo Health, Natural Cycles, and Clue, named key players in reports, are building databases of cycles, symptoms, and hormonal patterns from tens of millions of women. Their true value lies not in the apps but in the datasets that will train medical AI models. In the coming months, we'll see these platforms start selling de-identified data to pharma companies developing drugs for menopause and PCOS. This is the hidden but most profitable segment of their business.
- Manufacturers of "menopausal collagen." The Anglia Ruskin University study gave them the perfect message: "Collagen is not for wrinkles but for structural support during hormonal transition." This allows selling the product not as a cosmetic but as a nutraceutical, increasing willingness-to-pay by 40-60%. Brands like Kollo Health are already building their entire storytelling around menopause.
- Screening and prevention initiatives. Virtual runs like Pink Strides and donations to the Mayo Clinic Women's Health Research Center are not just charity. They collect data on physical activity and reach, which insurance companies will use to calculate risks and personalized health insurance rates for women. Wellness activism becomes an underwriting tool.
Losers:
- Traditional gynecology clinics without a digital component. The flow of young women with PCOS and perimenopausal concerns is moving to online platforms. In May 2026, Team WHIP is launching a virtual wellness tour covering reproductive, mental, and spiritual health. These are low-cost, home-accessible formats that eat into the audience of offline clinics. If a doctor cannot offer telehealth and remote hormone monitoring, they lose.
- Brands of "glossy anti-aging" without hormonal expertise. Creams that promise "erased wrinkles" in two weeks but ignore hormonal aging lose trust. Consumers aged 40+ now want to hear about estrogen, SHBG, and bone density. Brands without doctors and endocrinologists on staff will be left behind.
- Manufacturers of sugary drinks and ultra-processed snacks. Campaigns like North Dakota HHS directly urge "drink water instead of sugary drinks." But more importantly, new research links high glycemic index to worsening PCOS symptoms. This hits the entire category of sugary sodas, which will now be perceived not just as "unhealthy" but as "exacerbating hormonal imbalance."
What the Media Isn't Saying
This beautiful picture of May health hides an uncomfortable truth: the monetization of women's hormonal health occurs by creating a permanent state of "risk." Women are convinced that their hormones are a constant vulnerability requiring continuous monitoring, tracking, and correction. Femtech apps don't just help; they gamify anxiety. Every notification like "today you are in a low-energy phase" or "your progesterone is likely dropping" is a soft form of fear marketing that converts into purchases of supplements, consultations, and tests.
Moreover, the problem of data quality is downplayed. The ginger study is a gold-standard RCT. But for every such study, there are hundreds of products with herbal extracts whose dosages, bioavailability, and interactions with prescription drugs have never been tested clinically. Ginger really works. But a €14 ginger latte at a wellness café does not. The industry sells the "halo effect" of a scientific ingredient in a form that lacks proven efficacy. This is the main gray area that glossy magazines ignore.
Another inconvenient fact: the huge gender gap in research funding persists despite all the awareness campaigns. The fact that quality RCTs on ginger for PCOS are only now emerging speaks to decades of neglect of female endocrine pathologies. May events create an illusion of a solved problem, while in reality we are at the beginning of the journey.
Forecast: Next 30 Days and 90 Days
30 days (to mid-June 2026):
After National Women's Health Week (May 10-16), we will see a wave of commercial announcements disguised as "supporting awareness." FMCG giants will launch limited-edition products with "female" nutrients: yogurts with myo-inositol, collagen bars, ginger teas. Major retailers (Target, CVS) will set up special "Women's Wellness" shelves combining supplements, femtech gadgets, and skincare. The placement fee for a brand on such a shelf could reach $50,000 per month, becoming a new sales channel for startups. We also expect Flo Health or Clue to announce a new funding round, leveraging the May information buzz.
90 days (August 2026):
By the end of summer, we will see the birth of "menopausal luxury." Just as premium mature skincare emerged 10 years ago, a premium segment for hormonal aging will now arise. This will be collagen drinks at $12 per bottle with added adaptogens, positioned as "internal hormonal aesthetics." We predict the launch of the first luxury brand that openly says: "This line is for women 45+, and it costs three times more than regular." They will use data from the Anglia Ruskin University collagen study to justify the price.
Simultaneously, the first major scandal involving femtech platform data will occur. A leak or sale of aggregated hormonal profiles will spark outrage and lead to calls for regulation in the US and EU. This will spur the growth of "sovereign" women's apps with data storage within the EU, adding +30% to their operating costs but becoming a competitive advantage.
Finally, August will show whether the "ginger trend" becomes a real category. If brands like Pukka or Yogi Tea launch clinically validated "PCOS Blends" with certified gingerol content, the functional tea market for women's health will grow by 25%. If it remains at the marketing level, a consumer backlash will occur, and trust in herbal "hormonal solutions" will drop. The next 90 days are a test of maturity for the entire women's health industry.
— Editorial Team
